Treatment strategies in oligo-metastatic prostate cancer - a nation-wide survey.

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY

Urologia Internationalis Pub Date : 2025-04-14 DOI:10.1159/000545630

Angelika Borkowetz, Bernd Wullich, Matthias Saar, Nina Schmidt-Hegemann, Johannes Linxweiler

{"title":"Treatment strategies in oligo-metastatic prostate cancer - a nation-wide survey.","authors":"Angelika Borkowetz, Bernd Wullich, Matthias Saar, Nina Schmidt-Hegemann, Johannes Linxweiler","doi":"10.1159/000545630","DOIUrl":null,"url":null,"abstract":"Introduction: Metastasis-directed therapy (MDT) is a promising approach for recurrent or de novo oligo-metastatic castration-sensitive prostate cancer (omCSPC). The aim of this study was to evaluate the treatment approaches in omCSPC among German physicians.Methods: An anonymous online questionnaire was sent via survio.com to the members of the German Societies of Urology and Radiooncology.Results: Participants (n=166; 33% urologists, 66% radiooncologists) define omCSPC as ≤ 3 (31%) or ≤ 4 (58%) metastases. Multimodal therapy consisting of local therapy of the primary tumor, MDT and androgen deprivation therapy (ADT) was favored. For local therapy, radiotherapy was the preferred approach (radiotherapy: 84%, prostatectomy: 16%). 77% and 76% considered MDT as (very) highly important in synchronous and metachronous omCSPC, respectively. 80% would complement MDT with time-limited ADT. Compared to urologists, radiooncologists more often include cases with ≥ 3 metastases (p=0.006), see a higher importance of radiotherapy (p=0.023), a lower importance of prostatectomy (p<0.001) as well as a higher importance of MDT (in de novo p=0.038, in metachronous p=0.010).Conclusion: In conclusion, MDT with time-limited ADT is a common treatment strategy in omCSPC. Especially in synchronous omCSPC, radiotherapy as local treatment for the primary is the preferred option rather than radical prostatectomy.","PeriodicalId":23414,"journal":{"name":"Urologia Internationalis","volume":" ","pages":"1-20"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Internationalis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545630","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Metastasis-directed therapy (MDT) is a promising approach for recurrent or de novo oligo-metastatic castration-sensitive prostate cancer (omCSPC). The aim of this study was to evaluate the treatment approaches in omCSPC among German physicians.

Methods: An anonymous online questionnaire was sent via survio.com to the members of the German Societies of Urology and Radiooncology.

Results: Participants (n=166; 33% urologists, 66% radiooncologists) define omCSPC as ≤ 3 (31%) or ≤ 4 (58%) metastases. Multimodal therapy consisting of local therapy of the primary tumor, MDT and androgen deprivation therapy (ADT) was favored. For local therapy, radiotherapy was the preferred approach (radiotherapy: 84%, prostatectomy: 16%). 77% and 76% considered MDT as (very) highly important in synchronous and metachronous omCSPC, respectively. 80% would complement MDT with time-limited ADT. Compared to urologists, radiooncologists more often include cases with ≥ 3 metastases (p=0.006), see a higher importance of radiotherapy (p=0.023), a lower importance of prostatectomy (p<0.001) as well as a higher importance of MDT (in de novo p=0.038, in metachronous p=0.010).

Conclusion: In conclusion, MDT with time-limited ADT is a common treatment strategy in omCSPC. Especially in synchronous omCSPC, radiotherapy as local treatment for the primary is the preferred option rather than radical prostatectomy.

查看原文本刊更多论文

低转移性前列腺癌的治疗策略-一项全国性调查。

导论：转移导向治疗（MDT）是治疗复发性或新发低转移性去势敏感前列腺癌（omCSPC）的一种很有前景的方法。本研究的目的是评估德国医生对omCSPC的治疗方法。方法：通过survio.com向德国泌尿外科和放射肿瘤学学会会员发送匿名在线问卷。结果：参与者(n=166；33%泌尿科医生、66%放射肿瘤科医生将omCSPC定义为≤3个（31%）或≤4个（58%）转移灶。首选由原发肿瘤局部治疗、MDT和雄激素剥夺治疗（ADT）组成的多模式治疗。对于局部治疗，首选放射治疗（放疗：84%，前列腺切除术：16%）。77%和76%的人分别认为MDT在同步和同步omCSPC中（非常）非常重要。80%的人会用有时限的ADT补充MDT。与泌尿科医生相比，放射肿瘤科医生更多地纳入≥3个转移灶的病例（p=0.006），放疗的重要性更高（p=0.023），前列腺切除术的重要性较低(p)结论：总之，MDT联合有时限的ADT是omCSPC的常见治疗策略。特别是在同步omCSPC中，放疗作为局部治疗是首选，而不是根治性前列腺切除术。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urologia Internationalis 医学-泌尿学与肾脏学

CiteScore

3.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： Concise but fully substantiated international reports of clinically oriented research into science and current management of urogenital disorders form the nucleus of original as well as basic research papers. These are supplemented by up-to-date reviews by international experts on the state-of-the-art of key topics of clinical urological practice. Essential topics receiving regular coverage include the introduction of new techniques and instrumentation as well as the evaluation of new functional tests and diagnostic methods. Special attention is given to advances in surgical techniques and clinical oncology. The regular publication of selected case reports represents the great variation in urological disease and illustrates treatment solutions in singular cases.